Literature DB >> 15067352

Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.

Paula M de Angelis1, Bjørg Fjell, Katherine L Kravik, Terje Haug, Siv H Tunheim, Wenche Reichelt, Marzieh Beigi, Ole Petter Clausen, Eivind Galteland, Trond Stokke.   

Abstract

5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer, but resistance to 5-FU remains a major obstacle to successful therapy. We generated 5-FU-resistant derivatives of the HCT116 human colon cancer cell line by serial passage of these cells in the presence of increasing 5-FU concentrations in an attempt to elucidate the biological mechanisms involved in resistance to 5-FU. Two resultant resistant derivatives, HCT116 ResB and ResD, were characterized for resistance phenotypes, genotypes, and gene expression using cells maintained long-term in 5-FU-free media. Compared to parental HCT116 cells that respond to 5-FU challenge by inducing high levels of apoptosis, ResB and ResD derivatives had significantly reduced apoptotic fractions when transiently challenged with 5-FU. ResB and ResD cells were respectively 27- and 121-fold more resistant to 5-FU, had increased doubling times, and significantly increased plating efficiencies compared to the parental cells. Both resistant derivatives retained the wild-type TP53 genotype, TP53 copy number and CGH profile characteristic of the parental line. Alterations in gene expression in the resistant derivatives compared to the parental line were assessed using oligonucleotide microarrays. Overall, the 5-FU-resistant derivatives were characterized by reduced apoptosis and a more aggressive growth phenotype, consistent with the observed up-regulation of apoptosis-inhibitory genes (e.g., IRAK1, MALT1, BIRC5), positive growth-regulatory genes (e.g., CCND3, CCNE2, CCNF, CYR61), and metastasis genes (e.g., LMNB1, F3, TMSNB), and down-regulation of apoptosis-promoting genes (e.g., BNIP3, BNIP3L, FOXO3A) and negative growth-regulatory genes (e.g., AREG, CCNG2, CDKN1A, CDKN1C, GADD45A). 5-FU metabolism-associated genes (e.g., TYMS, DTYMK, UP) and DNA repair genes (e.g., FEN1, FANCG, RAD23B) were also up-regulated in one or both resistant derivatives, suggesting that the resistant derivatives might be able to overcome both 5-FU inhibition of thymidylate synthase and the DNA damage caused by 5-FU, respectively. Development of 5-FU resistance thus appears to encompass deregulation of apoptosis-, proliferation-, DNA repair-, and metastasis-associated regulatory pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067352

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  35 in total

Review 1.  The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death.

Authors:  T R Burton; S B Gibson
Journal:  Cell Death Differ       Date:  2009-01-09       Impact factor: 15.828

2.  An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer.

Authors:  Zhenshu Wen; Zhi-Ping Liu; Zhengrong Liu; Yan Zhang; Luonan Chen
Journal:  J Am Med Inform Assoc       Date:  2012-09-11       Impact factor: 4.497

3.  Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.

Authors:  Glenda Nicioli da Silva; Elaine Aparecida de Camargo; Daisy Maria Favero Salvadori
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

4.  Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway.

Authors:  Hyun-Jung An; Hayyoung Lee; Sang-Gi Paik
Journal:  Mol Cells       Date:  2011-05-11       Impact factor: 5.034

5.  Expression and subcellular localization of BNIP3 in hypoxic hepatocytes and liver stress.

Authors:  Mallikarjuna R Metukuri; Donna Beer-Stolz; Rajaie A Namas; Rajeev Dhupar; Andres Torres; Patricia A Loughran; Bahiyyah S Jefferson; Allan Tsung; Timothy R Billiar; Yoram Vodovotz; Ruben Zamora
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-15       Impact factor: 4.052

6.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

7.  Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression.

Authors:  Anke H Sillars-Hardebol; Beatriz Carvalho; Meike de Wit; Cindy Postma; Pien M Delis-van Diemen; Sandra Mongera; Bauke Ylstra; Mark A van de Wiel; Gerrit A Meijer; Remond J A Fijneman
Journal:  Tumour Biol       Date:  2010-01-21

8.  Immunoscreening of the extracellular proteome of colorectal cancer cells.

Authors:  Susanne Klein-Scory; Salwa Kübler; Hanna Diehl; Christina Eilert-Micus; Anke Reinacher-Schick; Kai Stühler; Bettina Warscheid; Helmut E Meyer; Wolff Schmiegel; Irmgard Schwarte-Waldhoff
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

9.  Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.

Authors:  C Elizabeth Caldon; Elizabeth A Musgrove
Journal:  Cell Div       Date:  2010-01-17       Impact factor: 5.130

10.  Enrichment map: a network-based method for gene-set enrichment visualization and interpretation.

Authors:  Daniele Merico; Ruth Isserlin; Oliver Stueker; Andrew Emili; Gary D Bader
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.